147 related articles for article (PubMed ID: 22251023)
1. An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression.
Prakash A; Lobo E; Kratochvil CJ; Tamura RN; Pangallo BA; Bullok KE; Quinlan T; Emslie GJ; March JS
J Child Adolesc Psychopharmacol; 2012 Feb; 22(1):48-55. PubMed ID: 22251023
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
3. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.
Atkinson SD; Prakash A; Zhang Q; Pangallo BA; Bangs ME; Emslie GJ; March JS
J Child Adolesc Psychopharmacol; 2014 May; 24(4):180-9. PubMed ID: 24813026
[TBL] [Abstract][Full Text] [Related]
4. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.
Emslie GJ; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS
J Child Adolesc Psychopharmacol; 2014 May; 24(4):170-9. PubMed ID: 24815533
[TBL] [Abstract][Full Text] [Related]
5. Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
Emslie GJ; Wells TG; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS
J Child Adolesc Psychopharmacol; 2015 May; 25(4):293-305. PubMed ID: 25978741
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
Brecht S; Desaiah D; Marechal ES; Santini AM; Podhorna J; Guelfi JD
J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder.
Lobo ED; Quinlan T; Prakash A
Clin Pharmacokinet; 2014 Aug; 53(8):731-40. PubMed ID: 24989060
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine in the long-term treatment of major depressive disorder.
Raskin J; Goldstein DJ; Mallinckrodt CH; Ferguson MB
J Clin Psychiatry; 2003 Oct; 64(10):1237-44. PubMed ID: 14658974
[TBL] [Abstract][Full Text] [Related]
11. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.
Wohlreich MM; Martinez JM; Mallinckrodt CH; Prakash A; Watkin JG; Fava M
J Clin Psychopharmacol; 2005 Dec; 25(6):552-60. PubMed ID: 16282837
[TBL] [Abstract][Full Text] [Related]
12. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials.
Pangallo BA; Zhang Q; Desaiah D; Perahia DG; Detke MJ; Kennedy SH
Curr Med Res Opin; 2010 Nov; 26(11):2643-51. PubMed ID: 20932222
[TBL] [Abstract][Full Text] [Related]
14. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
15. Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials.
Mahableshwarkar AR; Affinito J; Reines EH; Xu J; Nomikos G; Jacobsen PL
CNS Spectr; 2020 Jun; 25(3):352-362. PubMed ID: 31199210
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
[TBL] [Abstract][Full Text] [Related]
17. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
Cowen PJ; Ogilvie AD; Gama J
Curr Med Res Opin; 2005 Mar; 21(3):345-56. PubMed ID: 15811202
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder.
Raskin J; Wiltse CG; Dinkel JJ; Walker DJ; Desaiah D; Katona C
J Clin Psychopharmacol; 2008 Feb; 28(1):32-8. PubMed ID: 18204338
[TBL] [Abstract][Full Text] [Related]
20. Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder.
Dunner DL; Wilson M; Fava M; Kornstein S; Munoz R; O'Reardon J; Trivedi M; Wohlreich M
Depress Anxiety; 2008; 25(5):E1-8. PubMed ID: 17621644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
